SEP 23·SEC EDGARLow
Denton John Russel sold $239K of CAI
Denton John Russel (See Remarks) sold 7,500 shares of Caris Life Sciences, Inc. (CAI) at $31.82 ($0.24M total) on 2026-09-22.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$CAI
Caris Life Sciences, Inc.
AlphAI earnings readSecond Quarter 2026 · AUG 5Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $CAIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $CAI in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $12.4M 2 txs
Denton John Russel1× · $239K
10b5-1 share of filings0%
Top stories · $CAIMore →
SEP 23·morningstar.com
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.
SEP 17·SEC EDGAR
Brille Brian J sold $12.1M of CAI
Brille Brian J (See Remarks) sold 400,000 shares of Caris Life Sciences, Inc. (CAI) at $30.33 ($12.13M total) on 2026-09-17.
CAI sentiment & insider activity
Recent CAI coverage spans insider activity, earnings and regulation.
In the last 30 days, CAI insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($12.4M). The most active reporter was Denton John Russel, See Remarks, with 1 filing.
What's driving CAI
Small insider sale likely has minimal price impact.
Potential sector-level upside optionality if FDA approval supports broader category acceptance.
Large insider sale may signal negative sentiment and put downward pressure on CAI stock.
The filing provides no new financial data or material events; likely neutral impact on the stock.
Large insider sell may signal lack of confidence, potentially pressuring the stock lower.
AlphAI scores every news story that mentions CAI with an AI model for sentiment and relevance, and aggregates insider trades from Caris Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CAI
Score
Denton John Russel sold $239K of CAI
Denton John Russel (See Remarks) sold 7,500 shares of Caris Life Sciences, Inc. (CAI) at $31.82 ($0.24M total) on 2026-09-22.
1 min readThis test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.
6 min readBrille Brian J sold $12.1M of CAI
Brille Brian J (See Remarks) sold 400,000 shares of Caris Life Sciences, Inc. (CAI) at $30.33 ($12.13M total) on 2026-09-17.
1 min readBeginning on September 14, 2026, representatives of Caris Life Sciences, Inc. intend to use an investor presentation in meetings with current and potential…
Caris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure Beginning on September 14, 2026, representatives of Caris Life Sciences, Inc. (the “ Company ”) intend to use an investor presentation (the “ Investor Presentation ”) in meetings with current and potential investors at the Morgan Stanley 24th An
1 min readSpetzler David Baxley sold $14.8M of CAI
Spetzler David Baxley (President) sold 597,212 shares of Caris Life Sciences, Inc. (CAI) at an average of $24.84 ($24.76–$25.32, $14.83M total) across 3 trades over 2026-09-03 to 2026-09-04.
1 min readCaris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Caris Life Sciences (NASDAQ: CAI) published a study in npj Precision Oncology on an AI tool for pancreatic cancer treatment. The tool, part of the Caris Molecular Tumor Board Report, predicts patient outcomes for two treatments, with median survival of 16 months for FOLFIRINOX vs. 9.9 months for gemcitabine plus nab-paclitaxel. The company's MI Cancer Seek test, FDA-approved in November 2024, includes this tool.
2 min read
Caris Life Sciences Is Up 73% Off Its Low. Is It Too Late to Buy?
Caris Life Sciences (CAI) stock rose 73% from its May low, closing at $24.58 on August 20. The rally followed record revenue of $263.71 million and raised full-year guidance. Analysts' target prices range from $25 to $36, with a mid-target of ~$25. Management highlighted potential margin expansion due to cost reductions and pricing gains, but the stock trades at 86x forward earnings, indicating high valuation.
2 min readTop Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance
Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
3 min read
Tech M&A deals: Citi, Kard Financial, CAI Software, LLumin, Providence Equity, Hometrack
The article lists recent tech M&A deals. Citigroup will acquire Kard Financial to bolster U.S. credit card rewards technology; terms were not disclosed and Citi said it is not material. CAI Software will buy LLumin to add predictive maintenance and asset management capabilities; terms not disclosed. Providence Equity will acquire Hometrack from ZPG to expand property data software.
4 min read
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences (Nasdaq: CAI) reported Q2 2026 revenue of $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services to $252.3 million. It completed about 59,200 clinical cases and posted 68% gross margin. 2026 revenue guidance was raised to $1.03 to $1.04 billion.
5 min read